Improved Local Skin Toxicity and Safety Profile
with ADC Co-Administration

On June 10, Alteogen, a bio-platform company, announced that it had released preclinical experimental results on the subcutaneous (SC) formulation of antibody-drug conjugates (ADC) using the recombinant human hyaluronidase ALT-B4 at the 'World ADC Summit Korea'.


During the oral presentation session, Professor Taehwan Kim from the College of Pharmacy at Daegu Catholic University presented findings on the pharmacokinetics (PK) and local tolerability of subcutaneous injection of ADC therapeutics using ALT-B4. In the subsequent poster session, it was explained that subcutaneous administration of ALT-B4 (substance name: berahyaluronidase alfa)-based ADCs improved absorption and reduced toxicity.


Professor Taehwan Kim of the College of Pharmacy at Daegu Catholic University is presenting on the pharmacokinetics and local tolerability of subcutaneous injection of ADC therapeutics using ALT-B4 at the World ADC Summit Korea. Alteogen

Professor Taehwan Kim of the College of Pharmacy at Daegu Catholic University is presenting on the pharmacokinetics and local tolerability of subcutaneous injection of ADC therapeutics using ALT-B4 at the World ADC Summit Korea. Alteogen

View original image

In this preclinical experiment, mini pigs were administered ALT-P7 (anti-HER2 ADC), an ADC developed by Alteogen, via intravenous (IV) injection, subcutaneous (SC) injection, or subcutaneous injection in combination with ALT-B4, and the results were compared. The experiment demonstrated that the group receiving ALT-B4 combination SC injection exhibited a faster absorption rate after administration, and showed enhanced systemic exposure and bioavailability compared to the group that did not receive ALT-B4.


In addition, marked improvements were observed in skin toxicity at the local injection site when ADCs were administered in combination with ALT-B4. This improvement showed a dose-dependent trend with ALT-B4.


Furthermore, in terms of hematological indicators such as absolute neutrophil count, triglycerides, and aspartate aminotransferase, the IV administration group showed a significant decrease in neutrophil count and increases in triglycerides and liver enzymes. In contrast, the ALT-B4 combination SC administration group exhibited less reduction in neutrophil count and improved increases in triglycerides and liver enzymes, indicating an improvement of the hematological drawbacks associated with ADC therapeutics.


Through these results, Alteogen identified the possibility that co-administration with ALT-B4 can simultaneously improve drug absorption, injection site tolerability, and systemic safety when ADCs are administered subcutaneously. The company expects that the subcutaneous formulation using ALT-B4 could become a breakthrough in the highly competitive ADC market and anticipates more partnership opportunities as a result.


Taeyeon Jun, CEO of Alteogen, stated, "In this preclinical study, we observed alleviated skin reactions at the injection site when ALT-B4 was co-administered, as well as improvements in pharmacokinetic indicators such as AUC and hematological safety markers such as absolute neutrophil count." He added, "This suggests that SC formulation using ALT-B4 could serve as a paradigm shift, optimizing not only the convenience of administration but also the pharmacokinetics and safety profile of ADC therapeutics."



He further commented, "Our partner Daiichi Sankyo is currently conducting a Phase 1 clinical trial of the Enhertu SC formulation using ALT-B4, demonstrating the potential of ALT-B4 in the ADC field and its advancement into clinical development. These results once again confirm, with Alteogen's data, the potential of ALT-B4 as a platform to enhance the competitiveness of ADCs, and we expect this will lead to expanded ADC partnerships."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing